-
POSTER
Cost-effectiveness of lopinavir/r tablets compared to atazanavir + ritonavir in
antiretroviral experienced
patients in the UK, Spain, Italy, and France based on
results from BMS AI424-045
KN Simpson, W Jones, R Rajagopalan, B Dietz
PDF Poster
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Efficacy and safety of lopinavir/r and atazanavir without a nucleoside backbone
in
antiretroviral therapy
experienced HIV-infected subjects
DA Parks, HC Jennings, CW Taylor, et al
PDF
Poster
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Tolerability and preference of lopinavir/ritonavir (Kaletra) capsules versus
tablets as
single agent
therapy (IMANI-2)
J Gathe, B Lipman, B Miguel, et al
PDF Poster
Abstract
-
POSTER
Lack of sex differences in once-daily lopinavir/ritonavir (LPV/r)
pharmacokinetic (PK
I Ofotokun, S Chuck, M Palau, et al
PDF Poster
Abstract
-
POSTER
Significant improvements in self-reported gastrointestinal (GI) tolerability,
quality of life
(QoL), patient
satisfaction, and adherence with
lopinavir/ritonavir (LPV/r) after switching
from BID soft-gel capsule
(SGC) to
BID tablets (TAB)
S Schrader, SK Chuck, LW Rahn, et al
PDF Poster
Abstract
-
POSTER
Improvements in self-reported adherence &
gastrointestinal adverse effects (AEs) with
lopinavir/ritonavir (LPV/r) after
switching from soft-gel capsule (SGC) to tablet (TAB) varies
by ethnicity
S Schrader, SK Chuck, LW Rahn, et al
PDF Poster
Abstract
-
POSTER
Relationship Between Time to Viral Load Suppression and First Month
Adherence to Prescribed
Antiretroviral Therapy
RA Rode, BC Vrijens, AC Lange, et al
PDF Poster
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Lipid-profile of lopinavir/ritonavir (LPV/r) in an 18-month French observational
prospective cohort
(Kaleobs cohort)
M Dupon, J-Mi Livrozet, L Morand-Joubert, et al
PDF Poster
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Efficacy of lopinavir/ritonavir (LPV/r) in clinical practice: an 18-month
observational prospective
cohort of 1315 patients (Kaleobs cohort
J-M Livrozet, M Dupon, L Morand-Joubert, et al
PDF Poster
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Impact of a lopinavir/ritonavir (LPV/ r) monotherapy on self-reported side
effects and global
health
perception among antiretroviral-naive
patients: 48-week analysis of the MONARK Trial
B Spire, F Marcellin, IC Codar, et al
PDF Poster
Abstract
-
POSTER
Predicted pharmacokinetics of lopinavir after multiple dose administration of
lopinavir/
ritonavir
tablet to pediatric patients
W Liu, CE Klein, KC Marsh, et al
PDF Poster
Abstract
-
POSTER
Pharmacokinetics of lopinavir and ritonavir after multiple dose administration
of lopinavir/
ritonavir
tablet co-administered with efavirenz
CE Klein, Y Cai,
Y-L Chiu,
et al
PDF Poster
Abstract
-
POSTER
Gastrointestinal Complaints and
use of Acid Reducing Agents are frequent in patients treated
with
Antiretrovirals
E Toma , N Ackad , S Auger , J Sampalis
PDF Poster
Abstract
-
P-glycoprotein is inhibited by lopinavir and low-dose ritonavir in HIV-infected
patients and in healthy
men
C Wyen, G Fatkenheuer, R Aarnoutse. et al
Abstract
-
Triglycerides and small, dense low-density lipoprotein in HIV infected patients
treated with
lopinavir/ritonavir as a component of the first combination
antiretroviral therapy
L Magenta, W O Richter, M Opravil, et al
Abstract
-
Second
line lopinavir/ritonavir containing therapy is effective without major side
effects after failing
first line NNRTI containing regimens: 12 months follow-up
study at Mulago Hospital Adult Infectious
Diseases Clinic
Ba Castelnuovo, F Lutwama, PMwebase, et al
Abstract
-
Plasma lopinavir levels in a group of pregnant women on lopinavir, ritonavir,
zidovudine, and
lamivudine
K Manavi, A McDonald, Al Al-Sharqui
Abstract
-
Lipids and lipoproteins in HIV-subjects treated with
lopinavir/ritonavir (L) or atazanavir/ritonavir
(A) based antiretroviral therapy
A Trein, E Schnaitmann, W O Richter
Abstract
-
Exploring the feasibility of dried blood spots for quantification of lopinavir,
nevirapine and efavirenz
concentrations
L Else, L Dickinson, M Schellenberger, et al
Abstract
-
Placental transfer of lopinavir, saquinavir, and ritonavir
K Weizsaecker, C Feiterna, JP Siedentopf, et al
Abstract
-
The
assessment of multi-locus gene effects upon lopinavir pharmacokinetics
A Owen, T Mahungu, C Cook, et al
Abstract
-
Different rates of early viral load reduction with nevirapine or
lopinavir/ritonavir-based combination
antiretroviral therapies in pregnant women
C Bell, N Desmond, GP Taylor
Abstract
-
Safety assessment of lopinavir/ritonavir (LPV/r) in HIV+ and hepatitis C (HCV)
co-infected
patients
P Cote, C Cooper, JG Baril, et al
Abstract
-
Crossover, steady-state comparison of lopinavir/ritonavir (LPV/r)
pharmacokinetics (PK) in women
of colour
IR McNicholl, PGerman, D Cohan, et al
Abstract
-
Failure of lopinavir/ritonavir-containing regimen with newly selected PI
resistance mutations in an
antiretroviral nave
patient
S Koch, A Kroidl, M Oette, et al
Abstract
-
Low
incidence of severe liver events (SLE) in HIV patients with and without
hepatitis C or B
coinfection receiving lopinavir/ritonavir (LPV/r)
I Aguilar, S Vergara, A Rivero, et al
Abstract
-
Tolerability of lopinavir/ritonavir (LPV/r) liquid in HIV+ adults switched from
the soft gelatin capsule
(SGC)
J Toy, M Harris, J da Silva, et al
Abstract
-
Similar virologic and immunologic response to efavirenz or
lopinavir/ritonavir-based HAART in a large
cohort ofantiretroviral-naïve
patients with advanced HIV infection
F Pulido, J Arribas, S Moreno, et al
Abstract
-
Long-term follow-up of IMANI I: pilot study of the safety and efficacy of
lopinavir/ritonavir (LPV/r) as
single agent therapy (SAT) in HIV-1
antiretroviral (ARV)-nave
patients
J Gathe, Jr., C Mayberry, B Miguel, et al
Abstract
-
A
study on the performance of combination of Kaletra and saquinavir twice-daily
regimen on a group
of antiretroviral therapy experienced patients
K Manavi, C Burns, A McMillan
Abstract
|
